AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvABBV: AbbVie
2019-09-26 20:00:00
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes